[go: up one dir, main page]

EA201300996A1 - Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы - Google Patents

Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы

Info

Publication number
EA201300996A1
EA201300996A1 EA201300996A EA201300996A EA201300996A1 EA 201300996 A1 EA201300996 A1 EA 201300996A1 EA 201300996 A EA201300996 A EA 201300996A EA 201300996 A EA201300996 A EA 201300996A EA 201300996 A1 EA201300996 A1 EA 201300996A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
erbb3
patient
treatment
methods
Prior art date
Application number
EA201300996A
Other languages
English (en)
Inventor
Габриэла Гарсия
Уильям Кубасек
Виктор Мойо
Гэвин Макбет
Original Assignee
Мерримак Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерримак Фармасьютикалс, Инк. filed Critical Мерримак Фармасьютикалс, Инк.
Publication of EA201300996A1 publication Critical patent/EA201300996A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предложены способы подавления роста гормонорезистентных видов рака молочной железы путем контакта клеток опухоли с ингибитором ErbB3, предпочтительно антителом к ErbB3. Также предложены способы лечения гормонорезистентного рака молочной железы у пациента путем введения пациенту ингибитора связывания херегулина с ErbB3 или с гетеродимером ErbB2/ErbB3, причем ингибитором является антитело к ErbB3 или антитело к ErbB2. Способы лечения могут дополнительно включать выбор пациента с гормонорезистентным раком молочной железы и последующее введение пациенту ингибитора. Способы лечения могут также включать введение антагониста эстрогенного рецептора или ингибитора ароматазы пациенту и могут также включать введение пациенту по меньшей мере одного дополнительного противоракового средства, которое не является ингибитором ErbB3, антагониста эстрогенного рецептора или ингибитора ароматазы в комбинации с ингибитором ErbB3.
EA201300996A 2011-03-11 2012-03-12 Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы EA201300996A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451848P 2011-03-11 2011-03-11
US201261604281P 2012-02-28 2012-02-28
PCT/US2012/028792 WO2012125573A2 (en) 2011-03-11 2012-03-12 Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Publications (1)

Publication Number Publication Date
EA201300996A1 true EA201300996A1 (ru) 2014-01-30

Family

ID=45894680

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300996A EA201300996A1 (ru) 2011-03-11 2012-03-12 Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы

Country Status (12)

Country Link
US (1) US20140134170A1 (ru)
EP (1) EP2683741A2 (ru)
JP (1) JP2014508782A (ru)
KR (1) KR20140044796A (ru)
CN (1) CN103562226A (ru)
AU (1) AU2012229147B2 (ru)
BR (1) BR112013022882A2 (ru)
CA (1) CA2828075A1 (ru)
EA (1) EA201300996A1 (ru)
MX (1) MX2013010379A (ru)
SG (1) SG192844A1 (ru)
WO (1) WO2012125573A2 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (en) * 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
KR101798679B1 (ko) * 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
LT3110849T (lt) 2014-02-28 2020-12-10 Merus N.V. Antikūnai, surišantys erbb-2 ir erbb-3
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
CN104208069A (zh) 2014-05-08 2014-12-17 上海市计划生育科学研究所 双炔失碳酯组合物和疾病治疗方法
EP3283068A1 (en) 2015-04-17 2018-02-21 Merrimack Pharmaceuticals, Inc. Combination treatments with seribantumab
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
ITUB20160828A1 (it) * 2016-02-18 2017-08-18 Univ Degli Studi Genova Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro
SG11201806251WA (en) * 2016-03-15 2018-08-30 Merrimack Pharmaceuticals Inc Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
WO2018071440A1 (en) 2016-10-11 2018-04-19 Duke University Treatment of breast cancer
CN115737637A (zh) * 2017-01-10 2023-03-07 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
BR112019024230A2 (pt) * 2017-05-17 2020-06-09 Merus N.V. combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
AU2018312816B2 (en) 2017-08-09 2021-05-27 Merus N.V. Antibodies that bind EGFR and cMET
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗
CN115843256A (zh) * 2020-10-15 2023-03-24 上海翰森生物医药科技有限公司 抗erbb3抗体或其抗原结合片段及其医药用途
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2129396B1 (en) * 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
NZ597466A (en) 2007-03-01 2013-08-30 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions
JP2010526797A (ja) 2007-05-11 2010-08-05 エンゾン ファーマシューティカルズ，インコーポレーテッド Ｈｅｒ３のモジュレーションのためのｒｎａアンタゴニスト化合物
NZ589086A (en) * 2008-04-11 2012-09-28 Merrimack Pharmaceuticals Inc Human serum albumin (HSA) linkers and conjugates thereof
EP2318548B1 (en) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
JP2013507926A (ja) * 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
KR101798679B1 (ko) * 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
WO2011136911A2 (en) 2010-04-09 2011-11-03 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
TW201244719A (en) * 2010-07-09 2012-11-16 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
CA2828075A1 (en) 2012-09-20
US20140134170A1 (en) 2014-05-15
MX2013010379A (es) 2014-03-27
EP2683741A2 (en) 2014-01-15
BR112013022882A2 (pt) 2016-12-20
JP2014508782A (ja) 2014-04-10
SG192844A1 (en) 2013-09-30
AU2012229147A1 (en) 2013-03-14
NZ614427A (en) 2015-08-28
WO2012125573A3 (en) 2012-12-27
AU2012229147B2 (en) 2015-12-24
WO2012125573A2 (en) 2012-09-20
KR20140044796A (ko) 2014-04-15
CN103562226A (zh) 2014-02-05

Similar Documents

Publication Publication Date Title
EA201300996A1 (ru) Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы
MX343227B (es) Anticuerpos anti-erbb3.
MX344355B (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
MX2013009732A (es) Terapias de combinacion comprendiendo agentes anti-erbb3.
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
AR089083A1 (es) Anticuerpos para receptor de factor de crecimiento epidermico 3 (her3)
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
PH12014502419A1 (en) Specific binding proteins and uses thereof
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
EA201490369A1 (ru) Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
MX367042B (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
PH12014502641B1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
IN2014KN00871A (ru)
JO3370B1 (ar) طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EA201200597A1 (ru) Моноклональные антитела к прогастрину и их применение
CO6612253A2 (es) Agentas y antagonistas fijadores de notch y metodos para el uso de los mismos
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
WO2011146568A8 (en) Predicting response to a her inhibitor
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
UY35136A (es) Métodos para tratar el cáncer de ovario con antagonistas de dll4.
EA201490180A1 (ru) Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний